Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.64 |
| ▸ | MAOA | P21397 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920108 | 0.86 | MAOB (0.60) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5974513 | 0.85 | MAOB (0.68) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9373361 | 0.84 | MAOB (0.66) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL307233 | 0.84 | KMT2A (0.75) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27933717 | 0.84 | NR4A2 (0.65) | KMT2A | |
| SCHEMBL27801100 | 0.83 | MRGPRX4 (0.56) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL10799135 | 0.83 | KMT2A (0.51) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL8403547 | 0.82 | MAOB (0.64) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7045225 | 0.82 | MAOB (0.64) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27448957 | 0.82 | NR4A2 (0.46) | MAOBMAOAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | MAOB 1216/4885MAOA 1762/4885KMT2A 2460/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | MAOB 1059/4885MAOA 1045/4885KMT2A 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.